Patient info Open main menu

Renagel - patient leaflet, side effects, dosage

Contains active substance :

ATC code:

Dostupné balení:

Patient leaflet - Renagel

1. What Renagel is and what it is used for

Renagel contains sevelamer as the active ingredient. It binds phosphate from food in the digestive tract and so reduces serum phosphate levels in the blood.

Renagel is used to control the levels of phosphate in the blood of adult kidney failure patients on haemodialysis or peritoneal dialysis treatment.

Adult patients whose kidneys have failed and who are undergoing haemodialysis or peritoneal dialysis are not able to control the level of serum phosphate in their blood. The amount of phosphate then rises (your doctor will call this hyperphosphata­emia). Increased levels of serum phosphorus can lead to hard deposits in your body called calcification. These deposits can stiffen your blood vessels and make it harder for blood to be pumped around the body. Increased serum phosphorus can also lead to itchy skin, red eyes, bone pain and fractures.

Renagel may be used with other medicines which include calcium or vitamin D supplements to control the development of renal bone disease.

2. What you need to know before you take Renagel

Do not take Renagel:

  • if you have low levels of phosphate in your blood (your doctor will check this for you).
  • if you have bowel obstruction.
  • if you are allergic to sevelamer or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before taking Renagel if any of the following applies to you:

  • if you are not on dialysis
  • if you have swallowing problems
  • if you have problems with motility (movement) in your stomach and bowel
  • if you have symptoms of delayed emptying of stomach contents such as feeling of fullness, nausea and/or vomiting
  • if you have prolonged diarrhoea or pain in the abdomen (symptoms of active inflammatory bowel disease)
  • if you have undergone major surgery on your stomach or bowel

Talk to your doctor while taking Renagel:

  • if you experience severe abdominal pain, stomach or intestine disorders, or blood in the stool (gastrointestinal bleeding). These symptoms can be due to serious inflammatory bowel disease caused by sevelamer crystals deposit in your bowel. Contact your doctor who will decide on continuing the treatment or not.

Additional treatments :

Due to either your kidney condition or your dialysis treatment you may:

  • develop a low or high level of calcium in your blood. Since Renagel does not contain calcium your doctor might prescribe additional calcium tablets.
  • have a low amount of vitamin D in your blood. Therefore, your doctor may monitor the levels of vitamin D in your blood and prescribe additional vitamin D as necessary. If you do not take multivitamin supplements you may also develop low levels of vitamins A, E, K and folic acid in your blood and therefore your doctor may monitor these levels and prescribe supplemental vitamins as necessary.

Changing treatment :

When you switch from another phosphate binder to Renagel, your doctor might consider monitoring the levels of bicarbonate in your blood more closely because Renagel may decrease the levels of bicarbonate.

Special note for patients on peritoneal dialysis

You may develop peritonitis (infection of your abdominal fluid) associated with your peritoneal dialysis. This risk can be reduced by careful adherence to sterile techniques during bag changes. You should tell your doctor immediately if you experience any new signs or symptoms of abdominal distress, abdominal swelling, abdominal pain, abdominal tenderness, or abdominal rigidity, constipation, fever, chills, nausea or vomiting.

You should expect to be monitored more carefully for problems with low levels of vitamins A, D, E, K and folic acid.

Children and adolescents

The safety and efficacy in children (below the age of 18 years) has not been studied. Therefore Renagel is not recommended for use in this population.

Other medicines and Renagel

Tell your doctor if you are taking, have recently taken or might take any other medicines.

  • Renagel should not be taken at the same time as ciprofloxacin (an antibiotic).
  • If you are taking medicines for heart rhythm problems or for epilepsy, you should consult your doctor when taking Renagel.
  • The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus (medicines used in transplant patients) may be reduced by Renagel. Your doctor will advise you if you are taking these medicines.
  • In certain people taking levothyroxine (a thyroid hormone) and Renagel, increased levels of thyroid stimulating hormone (TSH, a substance in your blood which helps control your body’s chemical functions) may very rarely be observed. Therefore your doctor may monitor the levels of TSH in your blood more closely.

If you are taking medicine such as omeprazole, pantoprazole, or lansoprazole to treat heartburn, gastroesophageal reflux disease (GERD), or gastric ulcers, you should consult your doctor when taking Renagel.

Your doctor will check for interactions between Renagel and other medicines on a regular basis.

In some cases where Renagel should be taken at the same time as another medicine, your doctor may advise you to take this medicine 1 hour before or 3 hours after Renagel intake, or he/she may consider monitoring the blood levels of that medicine.

Pregnancy and breast-feeding

The safety of Renagel has not been established in pregnant or breast-feeding women. Renagel should only be given to pregnant or breast-feeding women if clearly needed.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

Driving and using machines

Renagel is unlikely to affect your ability to drive or to use machines.

3. How to take Renagel

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. He will base the dose on your serum phosphate level. The recommended starting dose of Renagel for adults and the elderly (>65 years) is two to four tablets with each meal 3 times a day.

Initially your doctor will check the levels of phosphate in your blood every 2–3 weeks and may adjust the dose of Renagel when necessary (between 1 and 10 tablets of 400 mg per meal) to reach an adequate phosphate level.

The tablets must be swallowed whole. Do not crush, chew or break into pieces prior to swallowing.

Patients taking Renagel should adhere to their prescribed diet and liquid intake.

If you take more Renagel than you should

In the event of a possible overdose you should contact your doctor immediately.

If you forget to take Renagel

If you have missed one dose, this dose should be omitted and the next dose should be taken at the usual time with a meal. Do not take a double dose to make up for a forgotten dose.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Since constipation may be a preceding symptom in very rare cases of blockages in your intestine, it is important to inform your doctor or pharmacist of this symptom before or during the use of Renagel.

The following side effects have been reported in patients taking Renagel:

Very common (may affect more than 1 in 10 people):

nausea, vomiting.

Common (may affect up to 1 in 10 people):

diarrhoea, indigestion, abdominal pain, constipation, flatulence.

Uncommon (may affect up to 1 in 100 people):

increased acidity of the blood.

Very rare (may affect up to 1 in 10000 people): hypersensitivity.

Not known (frequency cannot be estimated from the available data):

cases of itching, rash, abdominal pain, slow intestine motility (movement), inflammation of abnormal small pouches (called diverticula) in the large intestine, blockages in the intestine (signs include: severe bloating; abdominal pain, swelling or cramps; severe constipation), rupture in the intestine wall (signs include: severe stomach pain, chills, fever, nausea, vomiting, or a tender abdomen), serious inflammation of the large bowel (symptoms include: severe abdominal pain, stomach or intestine disorders, or blood in the stool [gastrointestinal bleeding]) and crystal deposit in the intestine have been reported.

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. Y ou can also report side effects directly via the national reporting system listed in By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Renagel

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the carton and bottle after “EXP”. The expiry date refers to the last day of that month.

Do not store this medicine above 25 °C. Keep the bottle tightly closed in order to protect from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What Renagel contains

  • – The active substance is sevelamer hydrochloride. Each tablet contains 400 mg sevelamer hydrochloride.

  • – The other ingredients are silica colloidal anhydrous and stearic acid, hypromellose (E464), diacetylated monoglycerides, iron oxide black (E172) and propylene glycol.

What Renagel looks like and contents of the pack

Renagel tablets are film coated, off white, oval tablets with Renagel 400 imprinted on one side.

The tablets are packed in high density polyethylene bottles with a child resistant polypropylene closure and an induction seal.

Pack sizes are:

1 bottle of 360 tablets

multipacks containing 720 tablets (2 bottles of 360 tablets)

multipacks containing 1080 tablets (3 bottles of 360 tablets)

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Genzyme Europe B.V.

Paasheuvelweg 25 1105 BP Amsterdam The Netherlands

Manufacturer:

Genzyme Ireland Limited

IDA Industrial Park

Old Kilmeaden Road

Waterford

Ireland

For any information about this medicine, please

Authorisation Holder:

België/Belgiqu­e/Belgien/

Luxembourg/Lu­xemburg

Sanofi Belgium

Tél/Tel: + 32 2 710 54 00

Efc^rapufl

Swixx Biopharma EOOD

Ten.: +359 (0)2 4942 480

Česká republika

sanofi-aventis, s.r.o.

Tel: +420 233 086 111

Danmark

Sanofi A/S

Tlf: +45 45 16 70 00

Deutschland

Sanofi-Aventis Deutschland GmbH

Tel: +49 (0)180 2 222010

Eesti

Swixx Biopharma OÜ

Tel: +372 640 10 30

EXÀàôa

sanofi-aventis AEBE

Tql: +30 210 900 1600

España

sanofi-aventis, S.A.

Tel: +34 93 485 94 00


contact the local representative of the Marketing

Lietuva

Swixx Biopharma UAB

Tel: +370 5 236 91 40


Magyarország

SANOFI-AVENTIS Zrt

Tel: +36 1 505 0050

Malta

Sanofi S.r.l.

Tel: +39 02 39394275

Nederland

Genzyme Europe B.V.

Tel: +31 20 245 4000

Norge

sanofi-aventis Norge AS

Tlf: + 47 67 10 71 00

Österreich

sanofi-aventis GmbH

Tel: + 43 1 80 185 – 0

Polska

sanofi-aventis Sp. z o.o.

Tel.: +48 22 280 00 00

Portugal

Sanofi – Produtos Farmacéuticos, Lda.

Tel: +351 21 35 89 400


France

sanofi-aventis France

Tél : 0 800 222 555

Appel depuis l’étranger : +33 1 57 63 23 23

Hrvatska

Swixx Biopharma d.o.o.

Tel: +385 1 2078 500


România

Sanofi Romania SRL

Tel: +40 (0) 21 317 31 36

Slovenija

Swixx Biopharma d.o.o.

Tel: +386 1 235 51 00


Ireland

sanofi-aventis Ireland Ltd T/A SANOFI

Tel: +353 (0) 1 4035 600

Island

Vistor hf.

Simi: +354 535 7000

Italia

Sanofi S.r.l.

Tel: 800 536 389

Knnpog

C.A. Papaellinas Ltd.

Tql: +357 22 741741

Latvija

Swixx Biopharma SIA

Tel: +371 6 616 47 50


Slovenská republika

Swixx Biopharma s.r.o.

Tel: +421 2 208 33 600

Suomi/Finland

Sanofi Oy

Puh/Tel: + 358 201 200 300

Sverige

Sanofi AB

Tel: +46 (0)8 634 50 00

United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525


This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: